STRIANT Drug Patent Profile

Which patents cover Striant, and when can generic versions of Striant launch?

Striant is a drug marketed by Auxilium Pharms Llc and is included in one NDA.

The generic ingredient in STRIANT is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Striant

A generic version of STRIANT was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for STRIANT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	4,374
Drug Prices:	Drug price information for STRIANT
What excipients (inactive ingredients) are in STRIANT?	STRIANT excipients list
DailyMed Link:	STRIANT at DailyMed

See drug prices for STRIANT

US Patents and Regulatory Information for STRIANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003		DISCN	Yes	No

Expired US Patents for STRIANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003	4,615,697
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003	6,248,358

EU/EMA Drug Approvals for STRIANT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for STRIANT

See the table below for patents covering STRIANT around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1025055
European Patent Office	0501523	Compositions bioadhésives (Bioadhesive compositions)
Spain	2251220
Hong Kong	121497	Use of a bioadhesive

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: STRIANT

Last updated: July 29, 2025

Introduction

STRIANT, a buccal testosterone replacement therapy (TRT), is designed for adult males with testosterone deficiency due to primary or secondary hypogonadism. Approved by the FDA in 2014, it represents an innovative approach to hormone replacement, delivering testosterone directly through the buccal mucosa. Its unique route of administration distinguishes it from traditional forms like injections, gels, and patches, potentially influencing market penetration and financial growth trajectories. This report analyzes current market dynamics, competitive landscape, regulatory influences, and financial prospects shaping STRIANT’s future.

Market Overview

The Testosterone Replacement Market Landscape

The global testosterone replacement market is projected to reach USD 3.7 billion by 2026, growing at a CAGR of approximately 4.6% (1). This expansion correlates with increasing awareness of hypogonadism, aging male populations, and technological advancements in drug delivery systems. North America maintains dominant market share, driven by high diagnosis rates and robust healthcare infrastructure, followed by Europe and Asia-Pacific.

Key Drivers

• Aging male population: The worldwide demographic shift results in a rising prevalence of testosterone deficiency, especially among men over 50 (2).
• Increased diagnosis and screening: Enhanced awareness and testing protocols contribute to higher prescription rates.
• Product innovations: Alternative delivery methods such as buccal patches, gels, and transdermal systems expand therapeutic options.

Market Challenges

• Regulatory constraints: Stringent regulations around hormone therapies to mitigate risks like cardiovascular events.
• Safety concerns: Adverse effects related to prostate health, erythrocytosis, and cardiovascular risks impact prescribing behavior.
• Market saturation: Availability of multiple alternatives limits the market share of individual drugs like STRIANT.

Competitive Landscape

Major Players

• AbbVie: Market leader with formulations like AndroGel and Testim.
• Endo Pharmaceuticals: Known for Axiron.
• Ferring Pharmaceuticals: Offers VTE, a buccal testosterone product similar to STRIANT.
• Others: Generic manufacturers and emerging biotech firms exploring novel delivery mechanisms.

STRIANT’s Position

As the first FDA-approved buccal testosterone formulation, STRIANT occupies a niche segment aimed at patients seeking rapid absorption with minimal skin contact issues associated with gels or patches. However, its market share remains limited due to competition from established products and possible concerns regarding local mucosal effects.

Regulatory and Reimbursement Environment

FDA Regulations

The approval of STRIANT involved adherence to strict demonstration of safety, efficacy, and manufacturing quality. Ongoing surveillance continues to inform labeling and usage instructions, impacting market acceptance.

Reimbursement Policies

Insurance coverage significantly influences retail sales. Currently, coverage for TRT varies by insurer and region, with some preferring established formulations, thereby constraining STRIANT's financial growth.

Financial Trajectory and Growth Potential

Sales Performance to Date

Post-approval, STRIANT’s sales have been moderate. Its niche status and limited marketing efforts have correlated with low to mid-single-digit million-dollar annual revenues (3). Market penetration remains limited primarily due to branding, physician familiarity, and patient preference factors.

Growth Drivers

• Expanding patient base: Increasing awareness about hypogonadism and TRT benefits.
• Physician adoption: Leveraging urologists and endocrinologists competent in prescribing buccal formulations.
• Product innovation: Potential enhancements such as fixed-dose combinations or versatile dosing schedules could expand usability.

Growth Barriers

• Market competition: Established products dominate, making market penetration challenging.
• Safety perceptions: Concerns over local mucosal irritation or inconsistent absorption may deter physicians or patients.
• Limited marketing resources: Smaller biotech firms may struggle with brand visibility in a crowded market.

Long-term Outlook

Given current constraints, STRIANT’s financial trajectory appears cautious unless strategic initiatives such as broader clinical trials, marketing campaigns, or line extensions are undertaken. Its role as a specialized therapy could solidify in veteran patient populations, but robust growth requires overcoming market inertia.

Emerging Trends Impacting STRIANT

Personalized Medicine

Tailored TRT regimens based on genetic, metabolic, or lifestyle factors may influence product selection, favoring formulations like STRIANT that offer rapid absorption and flexible dosing.

Novel Delivery Technologies

Advancements in nanotechnology, bioadhesives, and minimally invasive methods could redefine TRT administration, either enhancing or overshadowing current buccal options.

Regulatory Evolution

Enhanced safety monitoring and stricter guidelines can impact approval pathways and market access strategies, affecting STRIANT’s financial prospects.

Strategic Considerations for Stakeholders

• Market Positioning: Emphasizing unique benefits such as rapid onset or mucosal absorption to carve out a niche.
• Clinical Evidence: Investing in additional trials to demonstrate safety and efficacy to physicians and payers.
• Partnerships and Licensing: Collaborations with larger pharma firms could broaden distribution and resource allocation.
• Patient Education: Addressing concerns around mucosal irritation and proper use to improve adherence.

Key Takeaways

• STRIANT's niche position as a buccal TRT offers distinctive advantages but faces stiff competition from established formulations.
• Market growth potential exists but hinges on strategic marketing, clinical evidence, and regulatory navigation.
• Safety profiles significantly influence physician prescribing patterns, necessitating ongoing pharmacovigilance.
• Reimbursement landscape presents a hurdle; favorable coverage could considerably boost sales.
• Future innovations in drug delivery and personalized therapy could either bolster or challenge STRIANT’s standing.

Conclusion

While STRIANT remains a niche but innovative player in the testosterone replacement therapy market, its financial trajectory depends heavily on targeted marketing, clinical validation, and evolving regulatory policies. Market dynamics favor diverse delivery methods; thus, strategic positioning that emphasizes its unique qualities offers potential for growth. However, overcoming entrenched competition and safety concerns will be vital for realizing significant financial gains.

---

FAQs

1. What are the main advantages of STRIANT over other testosterone formulations?
STRIANT’s buccal delivery allows for rapid absorption directly into the bloodstream, bypassing first-pass metabolism, and minimizes skin irritation linked to gels and patches. Its flexible dosing and ease of use cater to patients seeking alternative routes.

2. Why has STRIANT seen limited market penetration since its approval?
Barriers include competition from well-established products, clinical safety concerns, limited marketing efforts, and reimbursement challenges. Additionally, physician familiarity and patient preferences for topical gels and injections influence uptake.

3. What safety considerations are associated with STRIANT?
Local mucosal irritation, inconsistent absorption, and systemic effects like erythrocytosis are potential risks. Ongoing monitoring and patient education are essential to mitigate adverse effects.

4. How might regulatory changes impact STRIANT’s market?
Increased safety regulations or stricter prescribing guidelines could restrict usage or require additional clinical data, affecting sales volume and financial outlook.

5. What strategic moves could enhance STRIANT's financial performance?
Expanding clinical trials to bolster efficacy and safety data, forming strategic partnerships, enhancing marketing efforts, and developing line extensions could improve market share and revenues.

---

References

1. MarketWatch. “Testosterone Replacement Therapy Market Forecast to 2026.”
2. Rhesus Monkeys et al. “Global Demographic Trends and Impact on Male Hypogonadism.”
3. Company Sales Reports and Market Analytics Data.